Equities research analysts forecast that Sangamo Therapeutics Inc (NASDAQ:SGMO) will report $18.30 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Sangamo Therapeutics’ earnings, with estimates ranging from $13.38 million to $22.35 million. Sangamo Therapeutics reported sales of $26.84 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 31.8%. The business is expected to announce its next earnings results on Thursday, February 27th.
On average, analysts expect that Sangamo Therapeutics will report full-year sales of $57.93 million for the current fiscal year, with estimates ranging from $52.00 million to $62.30 million. For the next year, analysts anticipate that the business will report sales of $111.07 million, with estimates ranging from $55.10 million to $240.50 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.10. Sangamo Therapeutics had a negative net margin of 136.73% and a negative return on equity of 27.32%. The business had revenue of $21.96 million for the quarter, compared to analyst estimates of $12.16 million. During the same period last year, the firm earned ($0.13) earnings per share. Sangamo Therapeutics’s revenue for the quarter was down 6.8% compared to the same quarter last year.
NASDAQ:SGMO opened at $9.85 on Friday. Sangamo Therapeutics has a 52 week low of $6.26 and a 52 week high of $13.91. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -14.07 and a beta of 2.79. The firm’s 50-day simple moving average is $9.03 and its 200 day simple moving average is $10.37.
Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new position in Sangamo Therapeutics during the second quarter worth about $229,000. Artal Group S.A. grew its stake in Sangamo Therapeutics by 1.3% during the second quarter. Artal Group S.A. now owns 405,000 shares of the biopharmaceutical company’s stock worth $4,362,000 after buying an additional 5,000 shares in the last quarter. Wells Fargo & Company MN grew its stake in Sangamo Therapeutics by 25.1% during the second quarter. Wells Fargo & Company MN now owns 821,420 shares of the biopharmaceutical company’s stock worth $8,847,000 after buying an additional 164,784 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in Sangamo Therapeutics during the second quarter worth about $308,000. Finally, Sector Gamma AS grew its stake in Sangamo Therapeutics by 5.4% during the second quarter. Sector Gamma AS now owns 251,698 shares of the biopharmaceutical company’s stock worth $2,711,000 after buying an additional 12,841 shares in the last quarter. 69.23% of the stock is currently owned by institutional investors and hedge funds.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Read More: What is Put Option Volume?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.